Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nektar Therapeutics

46.52
+2.194.94%
Volume:1.11M
Turnover:51.26M
Market Cap:884.74M
PE:-4.89
High:47.74
Open:44.25
Low:43.45
Close:44.33
52wk High:47.74
52wk Low:6.48
Shares:19.02M
Float Shares:16.64M
Volume Ratio:1.23
T/O Rate:6.70%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-9.5163
EPS(LYR):-8.6765
ROE:-440.80%
ROA:-31.57%
PB:-36.54
PE(LYR):-5.36

Loading ...

U.S. RESEARCH ROUNDUP-Hershey, Metlife, Voya Financial

Reuters
·
Jul 08

Nektar Therapeutics Closes $115 Million Public Offering with Full Exercise of Underwriters' Option

Reuters
·
Jul 03

BRIEF-Nektar Therapeutics Announces Pricing Of $100 Million Public Offering

Reuters
·
Jul 01

Nektar Therapeutics Files Prospectus for Public Offering to Support Drug Development Initiatives

Reuters
·
Jul 01

AeroVironment Posts Better-Than-Expected Earnings, Joins QuantumScape, Bumble, BlackBerry And Other Big Stocks Moving Higher On Wednesday

Benzinga
·
Jun 26

U.S. RESEARCH ROUNDUP- Fedex, Omnicom Group, Texas Instruments

Reuters
·
Jun 25

BTIG Raises Nektar Therapeutics' Price Target to $100 From $60, Buy Rating Maintained

MT Newswires Live
·
Jun 25

Nektar Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jun 25

Crude Oil Falls Sharply; US Current Account Deficit Widens In Q1

Benzinga
·
Jun 25

BUZZ-U.S. STOCKS ON THE MOVE-US airlines, Snowflake, Supermicro

Reuters
·
Jun 24

Sector Update: Health Care Stocks Edge Higher Premarket Tuesday

MT Newswires Live
·
Jun 24

BRIEF-Rezolve-Ad Phase 2B Study Of Rezpegaldesleukin Meets Primary And Key Secondary Endpoints In Patients With Moderate-To-Severe Atopic Dermatitis

Reuters
·
Jun 24

Nektar Therapeutics' experimental eczema drug meets main goals of mid-stage trial

Reuters
·
Jun 24

Stocks to Watch: Nektar Therapeutics, Alset

Dow Jones
·
Jun 24

Nektar Therapeutics to Unveil Top-Line Data from Phase 2b Study of Rezpegaldesleukin for Atopic Dermatitis on June 24, 2025

Reuters
·
Jun 24

BRIEF-Nektar Therapeutics Increases Authorized Shares To 390 Million

Reuters
·
Jun 07

Nektar Therapeutics Amends Bylaws, Increases Authorized Shares and Announces Reverse Stock Split

Reuters
·
Jun 07

Nektar Therapeutics Announces 1-for-15 Reverse Stock Split Effective June 8, 2025

Reuters
·
Jun 05

Nektar Therapeutics Conducted Annual Stockholders Meeting

Reuters
·
May 28

Nektar Therapeutics' Chief Legal Officer Mark A. Wilson Reports Disposal of Common Shares

Reuters
·
May 22